<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826913</url>
  </required_header>
  <id_info>
    <org_study_id>8036</org_study_id>
    <nct_id>NCT04826913</nct_id>
  </id_info>
  <brief_title>High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization</brief_title>
  <acronym>TUMOVASC</acronym>
  <official_title>High Throughput Screening Device Based on 3D Nano-matrices and 3D Tumors With Functional Vascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Almost 85% of new therapeutic molecules are abandoned before the clinical trial stage. Most&#xD;
      of these failures currently concern cancer therapies.&#xD;
&#xD;
      In order to optimize the development of these molecules and allow the development of&#xD;
      precision medicine, an innovative screening device that is as close as possible to in vivo is&#xD;
      necessary.&#xD;
&#xD;
      For this reason, the platform the investigators are setting up takes into account tumor&#xD;
      vascularization as well as the 3D microenvironment.&#xD;
&#xD;
      The platform the investigators intend to set up is based on 4 cornerstones:&#xD;
&#xD;
        -  the formation of patient-derived organoids seems to be the best option to take into&#xD;
           account the microenvironment and cellular interactions.&#xD;
&#xD;
        -  the vascular network: the formation of a peri-tumoral vascular network, either by using&#xD;
           HUVECS cells or by using endothelial cells from the patient.&#xD;
&#xD;
        -  the extracellular matrix, and the set of proteins it contains, is a major element of in&#xD;
           vivo interaction. Moreover, the presence of a matrix is a key element for the&#xD;
           development of vascularization in vitro.&#xD;
&#xD;
        -  Functional tumor microenvironment: peri-tumor vascularization is necessary but not&#xD;
           sufficient to claim to recreate a tumor microenvironment. It must be functionalized, and&#xD;
           this implies the use of a microfluidic system.&#xD;
&#xD;
      This ready-to-use platform will be used on tumor biopsies of the patient, to constitute a&#xD;
      tool for personalized medicine. This could even be a future component of decision at&#xD;
      multidisciplinary board meetings.&#xD;
&#xD;
      The main objective of our research is the constitution of organoids derived from the patient&#xD;
      in order to select, via a screening device, the best anti-tumor therapy to administer to the&#xD;
      patient.&#xD;
&#xD;
      A secondary objective is to collect lymphocytes from the patient's blood in order to test the&#xD;
      effectiveness of therapies mediated by the immune system (immunotherapy).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Testing of anti-cancer drugs</measure>
    <time_frame>3 years</time_frame>
    <description>Obtaining organoids from healthy tissue and tumor tissue. The tests will used these organoids</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>NSCLC</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Organoids</intervention_name>
    <description>Use of an innovative device to improve the management of patients with NSCLC for precision medicine.&#xD;
The different drugs used can be conventional chemotherapy (cisplatin, carboplatin, pemetrexed), targeted therapies or immunotherapy molecules. It is also planned to use radiotherapy on our drug testing device.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  whole blood (2 sample of blood collected prior to surgery)&#xD;
&#xD;
        -  tumoral tissue (non small cell lung cancer)&#xD;
&#xD;
        -  lung tissue with no malignity&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with non-small cell bronchopulmonary cancer (NSCLC), at any stage, undergoing&#xD;
        surgery in the Thoracic Surgery Department of the New Civil Hospital, Strasbourg.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient whose age is ≥ 18 years old&#xD;
&#xD;
          -  Patient with non-small cell bronchopulmonary cancer (NSCLC), at any stage, undergoing&#xD;
             surgery in the Thoracic Surgery Department of the New Civil Hospital, Strasbourg.&#xD;
&#xD;
          -  Patient who agreed to participate in this observational study.&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Known hepatitis, known HIV&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
&#xD;
          -  Subject under guardianship or trusteeship&#xD;
&#xD;
          -  Inability to give informed information about the subject (subject in an emergency&#xD;
             situation, difficulties in understanding the subject)&#xD;
&#xD;
          -  Pregnant Women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Emmanuel FALCOZ</last_name>
    <phone>+33 3 88 11 67 68</phone>
    <email>pierre-emmanuel.falcoz@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph SEITLINGEER</last_name>
    <phone>+33 3 83 85 85 85</phone>
    <email>joseph.seitlinger@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Emmanuel FALCOZ</last_name>
      <phone>+33 3 88 11 67 68</phone>
      <email>pierre-emmanuel.falcoz@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Joseph SEITLINGER</last_name>
      <phone>+33 3 83 85 85 85</phone>
      <email>joseph.seitlinger@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Emmanuel FALCOZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>organoids</keyword>
  <keyword>drug testing</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

